Dynamics and persistence of CYP2D6 inhibition by paroxetine

Journal of Clinical Pharmacy and Therapeutics

Volumn 38, Issue 4, 2013, Pages 294-300

  Jurica J ^a   Zourkova A ^a  

^a MASARYK UNIVERSITY   (Czech Republic)

Author keywords

CYP2D6; disinhibition; paroxetine

Indexed keywords

ALPRAZOLAM; CYTOCHROME P450 2D6; DEXTROMETHORPHAN; DEXTRORPHAN; MIRTAZAPINE; PAROXETINE;

ANXIETY DISORDER; ARTICLE; CLINICAL ARTICLE; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG METABOLISM; FEMALE; GENOTYPE; HUMAN; MALE; PHENOTYPE;

CYP2D6; DISINHIBITION; PAROXETINE;

ADOLESCENT; ADULT; AGED; ALPRAZOLAM; ANXIETY; CYTOCHROME P-450 CYP2D6; DEPRESSION; DEXTROMETHORPHAN; DEXTRORPHAN; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PAROXETINE; YOUNG ADULT;

EID: 84879955565     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/jcpt.12042     Document Type: Article

References (35)

1. Vaswani M, Linda FK, Ramesh S,. Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review. Prog Neuropsychopharmacol Biol Psychiatry, 2003; 27: 85-102.
2. Bertelsen KM, Venkatakrishnan K, Von Moltke LL, Obach RS, Greenblatt DJ,. Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: comparison with fluoxetine and quinidine. Drug Metab Dispos, 2003; 31: 289-293.
3. Otton SV, Wu DF, Joffe RT, Cheung SW, Sellers EM,. Inhibition by fluoxetine of cytochrome-P450 2d6 activity. Clin Pharmacol Ther, 1993; 53: 401-409.
4. Correia MA, Ortiz deMontellano PR,. Inhibition of cytochrome P450 enzymes. In:, Montellano PROd, ed. Cytochrome P450: structure, mechanism, and biochemistry, 3 edn. USA, Boston: Kluwer Academic/Plenum Publishers, 247-322, 2005.
5. Lin JH, Lu AYH,. Interindividual variability in inhibition and induction of cytochrome P450 enzymes. Annu Rev Pharmacol Toxicol, 2001; 41: 535-567.
6. Pelkonen O, Turpeinen M, Hakkola J, et al,. Inhibition and induction of human cytochrome P450 enzymes: current status. Arch Toxicol, 2008; 82: 667-715.
7. Kobayashi K, Yamamoto T, Chiba K, et al,. The effects of selective serotonin reuptake inhibitors and their metabolites on S-Mephenytoin 4′-Hydroxylase activity in human liver-microsomes. Br J Clin Pharmacol, 1995; 40: 481-485.
8. Sistonen J, Sajantila A, Lao O, et al,. CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure. Pharmacogenet Genomics, 2007; 17: 93-101.
9. Kirchheiner J, Seeringer A,. Clinical implications of pharmacogenetics of cytochrome P450 drug metabolizing enzymes. Biochim Biophys Acta, Gen Subj, 2007; 1770: 489-494.
10. WHO. International classification of diseases X; classification of mental and behavioural disorders. In: WHO, F:00-F:99, Geneva 2010, World Health Organization, Available online: http://apps.who.int/classifications/icd10/ browse/2010/en. Accessed 17/02/2012.
11. Zimova G, Chladek J, Martinkova J, Beranek M,. HPLC determination of dextromethorphan and its metabolites in urine. Chem Listy, 2000; 94: 132-135.
12. Sachse C, Brockmoller J, Bauer S, Roots I,. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet, 1997; 60: 284-295.
13. Hamilton M,. Rating depressive patients. J Clin Psychiatry, 1980; 41: 21-24.
14. Hamilton M,. Diagnosis and rating of anxiety. Br J Psychiatry, 1969; 3: 79.
15. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K,. The Uku side-effect rating-scale-a new comprehensive rating-scale for psychotropic-drugs and a cross-sectional study of side-effects in neuroleptic-treated patients-preface. Acta Psychiatr Scand, 1987; 76: 1-100.
16. Rang ST, Field J, Irving C,. Serotonin toxicity caused by an interaction between fentanyl and paroxetine. Can J Anaesth -Journal Canadien D Anesthesie, 2008; 55: 521-525.
17. Hoetelmans RMW, Meenhorst PL, Mulder JW, et al,. Clinical pharmacology of HIV protease inhibitors: focus on saquinavir, indinavir, and ritonavir. Pharm World Sci, 1997; 19: 159-175.
18. Silver H,. Selective serotonin reuptake inhibitor augmentation in the treatment of negative symptoms of schizophrenia. Int Clin Psychopharmacol, 2003; 18: 305-313.
19. Spina E, Avenoso A, Facciola G, et al,. Effect of fluoxetine on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenia. Int Clin Psychopharmacol, 1998; 13: 141-145.
20. Zourkova A, Ceskova E, Hadasova E, Ravcukova B,. Links among paroxetine-induced sexual dysfunctions, gender, and CYP2D6 activity. J Sex Marital Ther, 2007; 33: 343-355.
21. Zourkova A, Hadasova E,. Paroxetine-induced conversion of cytochrome P450 2D6 phenotype and occurence of adverse effects. Gen Physiol Biophys, 2003; 22: 103-113.
22. Zourkova A, Hadasova E, Pilarova L, Kuliskova O, Robes M,. Phenotype dynamics and its clinical correlates in patients treated by paroxetine. Eur Neuropsychopharmacol, 2003; 13: S237.
23. Feng Y, Pollock BG, Ferrell RE, et al,. Paroxetine: population pharmacokinetic analysis in late-life depression using sparse concentration sampling. Br J Clin Pharmacol, 2006; 61: 558-569.
24. Sindrup SH, Brosen K, Gram LF, et al,. The relationship between paroxetine and the sparteine oxidation polymorphism. Clin Pharmacol Ther, 1992; 51: 278-287.
25. Hiemke C, Hartter S,. Pharmacokinetics of selective serotonin reuptake inhibitors. Pharmacol Ther, 2000; 85: 11-28.
26. Liston HL, DeVane CL, Boulton DW, et al,. Differential time course of cytochrome P450 2D6 enzyme inhibition by fluoxetine, sertraline, and paroxetine in healthy volunteers. J Clin Psychopharmacol, 2002; 22: 169-173.
27. Crewe HK, Lennard MS, Tucker GT, Woods FR, Haddock RE,. The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes (Reprinted from Br J Clin Pharmacol, vol 34, pg 262-265, 1992). Br J Clin Pharmacol, 2004; 58: S744-S747.
28. Lind AB, Reis M, Bengtsson F, et al,. Steady-state concentrations of mirtazapine, N-Desmethylmirtazapine, 8-Hydroxymirtazapine and their enantiomers in relation to cytochrome P450 2D6 genotype, age and smoking behaviour. Clin Pharmacokinet, 2009; 48: 63-70.
29. Muck W, Ochmann K, Rohde G, Unger S, Kuhlmann J,. Influence of erythromycin pre- and co-treatment on single-dose pharmacokinetics of the HMG-CoA reductase inhibitor cerivastatin. Eur J Clin Pharmacol, 1998; 53: 469-473.
30. Sachse R, Brendel E, Muck W, et al,. Lack of drug-drug interaction between cerivastatin and nifedipine. Int J Clin Pharmacol Ther, 1998; 36: 409-413.
31. Chladek J, Zimova G, Beranek M, Martinkova J,. In-vivo indices of CYP2D6 activity: comparison of dextromethorphan metabolic ratios in 4-h urine and 3-h plasma. Eur J Clin Pharmacol, 2000; 56: 651-657.
32. Ito T, Kato M, Chiba K, Okazaki O, Sugiyama Y,. Estimation of the interindividual variability of cytochrome 2d6 activity from urinary metabolic ratios in the literature. Drug Metab Pharmacokinet, 2010; 25: 243-253.
33. Lotsch J, Rohrbacher M, Schmidt H, et al,. Can extremely low or high morphine formation from codeine be predicted prior to therapy initiation? Pain, 2009; 144: 119-124.
34. Zanger UM, Raimundo S, Eichelbaum M,. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. N-S Arch Pharmacol, 2004; 369: 23-37.
35. Spina E, Scordo MG, D'Arrigo C,. Metabolic drug interactions with new psychotropic agents. Fundam Clin Pharmacol, 2003; 17: 517-538.